Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

A Caged E3 Ligase Ligand for PROTAC-Mediated Protein Degradation with Light

18 December 2019, Version 1
Working Paper
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

A caging group has been appended to a widely used Von Hippel Lindau (VHL) E3 ligase ligand for targeted protein degradation with PROTACs. Proteolysis is triggered only after a short irradiation time allowing spatiotemporal control of the protein’s fate.

Keywords

E3 Ligase
protein degradation
von Hippel Lindau
PROTAC
Caged ligand
Light Activated

Supplementary materials

Title
Description
Actions
Title
SI Kounde Caged PROTAC Chemrxiv 10 Dec 2019
Description
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Now Published

A caged E3 ligase ligand for PROTAC-mediated protein degradation with light [opens in a new tab]
Cyrille S. Kounde, Maria M. Shchepinova, Charlie N. Saunders, Marcel Muelbaier, Mark D. Rackham, John D. Harling, Edward W. Tate journal article
Chemical Communications , Volume 56, Issue 41
Online publication date: 2020

Version History

Dec 18, 2019 Version 1

Metrics

4,417
1,229
0
Views
Downloads
Citations

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv.11350079.v1
D O I: 10.26434/chemrxiv.11350079.v1 [opens in a new tab]

Funding

EP/R512540/1

Author’s competing interest statement

M.M. and J.D.H are employees and shareholders of GlaxoSmithKline (GSK). E.W.T. is a Director and shareholder of Myricx Pharma Ltd. M.D.R is an employee of Merck Sharp & Dohme.

Share